 - Patients who have received drugs that are strong or moderate inhibitors andor inducers of CYP3A4 within 14 days prior to enrollment are not eligible; while on study, the following BCRP inhibitors cyclosporine, eltrombopag, gefitinib should be avoided if possible, and concomitant use of UGT1A1 inhibitors, such as diclofenac, ketoconazole, probenecid, silibinin, nilotinib and atazanavir, should be avoided because of potential for increased irinotecan toxicity 